Fundz
Free weekly newsletter

Get the free weekly contract digest

The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.

Weekly Digest

New new contracts, summarized for you

Straight to Inbox

No login, no app to check — it comes to you

Contract Trends

See who's moving and how much in your market

No credit card required Weekly contract digest

Tenvie Therapeutics Launches with $200 Million Investment to Transform Treatment of Neurological Diseases

Jan 08, 2025•over 1 year ago

Contract Type

partnership

South San FranciscoBiotechnologyHealth CareTherapeutics

Description

Tenvie Therapeutics has launched with a $200 million investment led by ARCH Venture Partners, F-Prime Capital, and Mubadala Capital, with a commitment to fundamentally alter the treatment paradigm for neurological diseases. The company is developing a portfolio of small molecules to address key drivers of disease.

Company Information

Company

Tenvie Therapeutics

Location

South San Francisco, California, United States

About

Tenvie is a biotechnology company committed to engineering small molecules that transform the treatment of neurological diseases. The company’s foundation is purpose-built with a diverse portfolio of small molecules and a proven team of CNS drug developers to rapidly deliver multiple clinical assets. Tenvie is advancing a pipeline of therapeutics focused on treating neurological, cardiometabolic, and ophthalmic diseases. Its portfolio of wholly owned, highly brain-penetrant, and precision-designed peripherally restricted small molecules address three key drivers of disease: resolving inflammation, rescuing metabolic dysfunction, and restoring lysosomal function. The company’s most advanced programs target NLRP3 and SARM1, with additional programs in preclinical development.

Predictive Intelligence
Strategic

ML-powered predictions for Tenvie Therapeutics's next move

Learn about Strategic plan

Agreement Insights

Based on industry data
Strategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.